Tesamorelin: Side Effects

Safety Notice#

Tesamorelin (Egrifta) is an FDA-approved medication with a well-characterized safety profile derived from multiple Phase 3 clinical trials involving over 800 patients. The adverse event data below are based on controlled clinical trial experience and FDA-approved prescribing information, providing a substantially more robust evidence base than exists for most investigational peptides.

Documented Adverse Effects from Clinical Trials#

The safety of tesamorelin was evaluated in two pivotal 26-week, randomized, double-blind, placebo-controlled Phase 3 trials and their extension studies, enrolling HIV-infected patients with excess abdominal fat. In the pooled analysis, the most commonly reported adverse reactions occurring in greater than or equal to 1% of tesamorelin-treated patients and at a rate exceeding placebo are summarized below.

Common Adverse Reactions (>1% incidence, exceeding placebo)#

Injection site reactions were the most frequently reported adverse events, occurring in approximately 8-13% of tesamorelin-treated patients compared to 5-7% of placebo-treated patients across the pivotal trials. These reactions included erythema, pruritus, pain, urticaria, irritation, swelling, and hemorrhage at the injection site. The reactions were generally mild in severity and rarely led to treatment discontinuation.

Arthralgia (joint pain) was reported in approximately 6-13% of tesamorelin-treated patients compared to 4-9% in placebo groups. This effect is consistent with GH-mediated stimulation of connective tissue and is a well-recognized class effect of GH-axis therapies.

Other adverse reactions reported at rates numerically exceeding placebo include:

• Pain in extremity (approximately 5-6%)
• Myalgia (approximately 3-4%)
• Peripheral edema (approximately 3-6%)
• Pruritus (non-injection site, approximately 2-4%)
• Night sweats (approximately 1-2%)
• Nausea (approximately 2-4%)
• Paresthesia (approximately 1-3%)

Metabolic Effects#

Glucose metabolism: Because growth hormone is a counter-regulatory hormone that opposes insulin action, tesamorelin treatment was associated with modest increases in fasting glucose levels. In the pivotal trials, mean fasting glucose increased by approximately 3-5 mg/dL from baseline in tesamorelin-treated patients. The incidence of new-onset type 2 diabetes was numerically higher in tesamorelin-treated patients (approximately 4%) compared to placebo (approximately 2%) in one trial analysis, though this did not reach statistical significance. Mean HbA1c changes were small (approximately 0.1% increase) but should be monitored in patients with pre-existing glucose intolerance.

IGF-1 elevation: Tesamorelin increased IGF-1 levels as an expected pharmacological effect. In clinical trials, approximately 47% of tesamorelin-treated patients had IGF-1 levels above the upper limit of the age-adjusted normal range at any point during treatment, compared to approximately 18% of placebo-treated patients. The prescribing information recommends monitoring IGF-1 levels during treatment and considering discontinuation if sustained IGF-1 elevations occur.

Lipid effects: Tesamorelin was generally associated with favorable lipid changes, including reductions in triglycerides. These effects are considered beneficial rather than adverse.

Hypersensitivity Reactions#

Anti-tesamorelin IgG antibodies developed in approximately 50% of patients treated with tesamorelin in the pivotal trials. In most patients, antibody development did not appear to affect efficacy or safety. However, rare cases of hypersensitivity reactions including urticaria, flushing, and pruritus were reported, and one case of anaphylaxis was noted in clinical trials.

Contraindications#

The FDA-approved prescribing information for tesamorelin lists the following absolute contraindications:

Active Malignancy#

Tesamorelin is contraindicated in patients with active malignancy, whether newly diagnosed or recurrent. Growth hormone stimulation can promote the growth of certain tumors, and tesamorelin-induced GH and IGF-1 elevations could theoretically accelerate tumor progression. Patients should be assessed for malignancy prior to initiating treatment. Tesamorelin has not been studied in patients with active malignancy.

Pregnancy#

Tesamorelin is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women. In animal reproduction studies, tesamorelin caused fetal toxicity at doses corresponding to clinical exposures. Women of childbearing potential should use effective contraception during treatment, and pregnancy testing is recommended prior to initiation and periodically during therapy.

Disruption of the Hypothalamic-Pituitary Axis#

Tesamorelin requires intact pituitary somatotroph function to stimulate GH release. Patients with disrupted hypothalamic-pituitary communication due to hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or other hypothalamic-pituitary disease are unlikely to respond to tesamorelin and should not receive the drug. Such patients require direct GH replacement (somatropin) rather than GHRH receptor stimulation.

Hypersensitivity#

Tesamorelin is contraindicated in patients with known hypersensitivity to tesamorelin or any component of the formulation, including mannitol. Given the reported development of anti-tesamorelin antibodies in approximately half of treated patients, clinicians should be vigilant for hypersensitivity reactions.

Drug Interactions#

Insulin and Diabetes Medications#

GH opposes insulin action through multiple mechanisms including promotion of hepatic glucose output and reduction of peripheral glucose uptake. Patients receiving insulin or oral hypoglycemic agents may require dose adjustments when starting or discontinuing tesamorelin. Blood glucose monitoring should be intensified during the initial weeks of tesamorelin therapy, particularly in patients with pre-existing type 2 diabetes or impaired glucose tolerance.

Cortisol-Modifying Drugs#

GH inhibits 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), the enzyme that converts inactive cortisone to active cortisol in peripheral tissues. In patients receiving glucocorticoid replacement for adrenal insufficiency, initiation of tesamorelin may unmask previously compensated cortisol deficiency by reducing the conversion of cortisone to cortisol. Glucocorticoid doses may need to be adjusted. Conversely, supraphysiological glucocorticoid doses can blunt GH secretion and attenuate tesamorelin's efficacy.

CYP450 Substrates#

Published data suggest that GH may modulate the activity of certain cytochrome P450 enzymes, including CYP3A4, CYP1A2, and CYP2C19. Drugs metabolized by these pathways may exhibit altered clearance during tesamorelin therapy. Particular caution is warranted for narrow therapeutic index drugs metabolized by these enzymes, including cyclosporine, sex steroids, anticonvulsants, and certain HIV protease inhibitors. Monitoring of drug levels and clinical response is advisable when co-administering tesamorelin with such medications.

Antiretroviral Therapy Interactions#

No formal drug interaction studies between tesamorelin and specific antiretroviral agents have been published. However, given the target population of HIV-infected patients, potential interactions with antiretroviral regimens should be considered. Some protease inhibitors and non-nucleoside reverse transcriptase inhibitors are metabolized by CYP3A4, and tesamorelin-induced GH changes could theoretically alter their metabolism. Clinical trial data did not reveal significant antiretroviral treatment failures attributable to tesamorelin.

Long-Term Safety Considerations#

Extension studies of up to 52 weeks provide the longest controlled safety data. Key long-term considerations include:

• The metabolic effects on glucose may become more clinically significant with prolonged treatment, particularly in patients with progressive insulin resistance
• Anti-tesamorelin antibody titers tended to plateau or decrease over time in extension studies, and neutralizing antibodies were uncommon
• IGF-1 elevations were sustained during continued treatment but generally remained within or modestly above the age-adjusted normal range
• Visceral fat reaccumulated upon discontinuation, raising the question of indefinite therapy and its long-term risk profile

Evidence Gaps#

• Long-term safety data beyond 52 weeks of continuous treatment are limited
• Cancer incidence in tesamorelin-treated patients has not been comprehensively evaluated in post-marketing surveillance
• Formal drug-drug interaction studies with specific antiretroviral agents have not been conducted
• Safety in non-HIV populations has not been established through controlled trials
• Effects of prolonged IGF-1 elevation on cancer risk remain a theoretical concern without definitive clinical data

Related Reading#

• Tesamorelin overview and research guide
• Tesamorelin dosing protocols
• Tesamorelin risks and legal status